New Agents, Targets Continue to Emerge in Sarcoma, Cementing Role for Immunotherapy

[D.ap]

"The buzz surrounding the potential role of immunotherapy in the sarcoma treatment landscape continues to grow as new agents and targets are identified, says Breelyn Wilky, MD.

Wilky, an associate professor of medicine, Sylvester Comprehensive Cancer Care, University of Miami Health System, recently sat down with Targeted Oncology to discuss recent findings of a trial investigating axitanib (Inlyta) and pembrolizumab (Keytruda) in soft tissue sarcomas, as well as the role she envisions for immunotherapy in the treatment of sarcoma.

TARGETED ONCOLOGY: You recently presented the phase II clinical trial looking at concurrent axitinib and pembrolizumab in advanced alveolar soft part sarcoma, and other soft tissue sarcomas. Can you provide an overview of the study?"


http://www.targetedonc.com/news/new-age ... unotherapy